ACE2 in tumor cells and tumor vasculature: Negligible intercellular transfer from cancer cells into endothelial cells

Zhi-Jie Liu\textsuperscript{1,a}, Yan Mei\textsuperscript{1,a}, Jiang-Li Lu\textsuperscript{2,a}, Jia-Bin Lu\textsuperscript{2,a}, Yun Cao\textsuperscript{2,a}, Mu-Yan Cai\textsuperscript{2}, Li-Sheng Zheng\textsuperscript{1}, Ming-Dian Wang\textsuperscript{1}, Li-Xia Peng\textsuperscript{1}, Yang Li\textsuperscript{3}, Bi-Jun Huang\textsuperscript{3}, Jin-Ping Yun\textsuperscript{3}, and Chao-Nan Qian\textsuperscript{1,4,5}

\textsuperscript{1} State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China
\textsuperscript{2} Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, PR China
\textsuperscript{3} Department of Pathology, Guangzhou Concord Cancer Center, Guangzhou 510555, PR China
\textsuperscript{4} Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou 510555, PR China

Received 1 March 2021, Accepted 6 July 2021, Published online 2 August 2021

Abstract – Cancer patients are more susceptible to severe coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Angiotensin-converting enzyme 2 (ACE2) is the functional host receptor for SARS-CoV-2 entering into human cells. Bioinformatics’ analyses have revealed that ACE2 is upregulated in some cancer cells. In the present study, we evaluated ACE2 protein expression levels in several common malignancies compared to non-cancerous normal tissues. ACE2 expression was elevated in colorectal adenocarcinoma, renal papillary cell carcinoma, gastric adenocarcinoma, and papillary renal cell carcinoma cancer. Moreover, elevated expression of ACE2 in cancer cells has been reported to be correlated with better patient prognosis in uterine corpus endometrial carcinoma, renal papillary cell carcinoma, and breast cancer [4, 5].

Key words: ACE2, SARS-CoV-2, COVID-19, Endothelial cells, Gastric cancer, Pancreatic cancer, Intercellular exchange.

Introduction

Angiotensin-converting enzyme 2 (ACE2) is gene mapped on the X chromosome and contains 18 exons. This gene codes an 805 amino acid type I transmembrane glycoprotein essential in the development of hypertension [1]. ACE2 and its genetic variants are secreted and circulate in the bloodstream [2]. Bioinformatics’ analyses have revealed elevated expression of ACE2 in colorectal adenocarcinoma, renal papillary cell carcinoma, pancreatic adenocarcinoma, gastric adenocarcinoma, and lung adenocarcinoma [3]. Moreover, elevated expression of ACE2 in cancer cells has been reported to be correlated with better patient prognosis in uterine corpus endometrial carcinoma, renal papillary cell carcinoma, and breast cancer [4, 5].

Another important role of ACE2 is that it is a receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which caused the recent COVID-19 pandemic. Given the fact that cancer patients infected with SARS-CoV-2 develop severe manifestations and possess a higher mortality rate in contrast with non-cancerous patients [6, 7], it is reasonable to ask whether ACE2 expressed by cancer cells is shared to normal cells, particularly blood vessel endothelial cells, which are critical for tumor development as well as SARS-CoV-2 infection [8].

The exchange of cell surface receptor proteins among cells in the immune system has been well documented [9]. The intercellular exchange of proteins among endothelial cells and cancer cells has also been observed [10, 11]. Moreover, intercellular exchange of transferrin receptors from cancer cells to surrounding fibroblasts has been reported [11]. In the present study, we evaluate ACE2 protein expression in different
cancers and explore whether ACE2 can transfer from cancer cells into endothelial cells.

Methods

Tissue samples and clinicopathological data

A total of 1175 paraffin-embedded tumor tissues and 1058 matched non-cancer tissues were collected from the Department of Pathology at Sun Yat-sen University Cancer Center (SYSUCC) with the approval of the Institutional Review Board. Tissues included malignancies from the thyroid, stomach, pancreas, colon and rectum, kidney (types 1 and 2 papillary renal cell carcinoma, chromophobe renal cell carcinoma), and testis. Among these tissues, 420 cases of colorectal cancer and renal cell carcinoma, chromophobe renal cell carcinoma), and pancreas, colon and rectum, kidney (types 1 and 2 papillary renal cell carcinoma), matched non-cancer tissues were collected from the Department of Pathology at Sun Yat-sen University Cancer Center with the approval of the Institutional Review Board. The ACE2 overexpressing lentivirus plasmid or control plasmid were co-transfected with the three package plasmids into 293T cells using TransInTM EL Transfection Reagent (TransGen Biotech, Beijing 100192, PR China) according to the product manual of the supplier. Four to six hours after transfection, the cell culture medium was changed with 4 mL fresh DMEM and supplemented with 20% FBS and incubated for 48 h. The media were then collected and centrifuged at 1250 rpm for 5 min to collect the supernatant for harvesting the virus. The cancer cells MGC803 and Capan-2 were seeded at an appropriate density to attach overnight for virus infection. The media were then discarded and changed with a virus containing a supernatant with 6 μg/mL polybrene. Eight hours post-infection, the cell culture media were changed with a fresh medium supplemented with 10% FBS and incubated for 24 h. Puromycin (2 μg/mL) was then added to the cells for stably infected cell selection. The stably infected cells were further isolated using fluorescence-activated cell sorting with MoFlo (Beckman-Coulter, Brea, CA 92821-6232).

Immunohistochemistry (IHC) analysis

ACE2 immunohistochemical (IHC) staining was performed using rabbit anti-human ACE2 Abs (Abcam, ab272690) with a working dilution of 1:50. The staining intensity and proportion of positive cells were assessed as previously reported [14–16]. Briefly, the staining intensity was scored 0, 1, 2, or 3 for a negative read, and the staining intensity was low, medium, or high. The proportion of positive cells were recorded as 0%, 1–10%, 11–50%, 50–80%, and 81–100%, which corresponded to scores 0, 1, 2, 3, and 4 respectively. IHC scores were determined by multiplying the intensity score and the positive cell proportion score ranging from 0 to 12. Two pathologists independently assessed the IHC scores, and the final IHC staining value was the mean value from the two pathologists’ scores. Patients were divided into the low expression or high expression group using the median IHC staining value as the cutoff value.

Cell culture

Human gastric cancer cell line MGC803 and pancreatic cancer cell line Capan-2 were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Human microvascular endothelial cells (HMVEC) were cultured in an EGM-2MV Bullet Kit medium (CC-3202, Lonza) supplemented with 10% FBS. All cells were grown in a 37 °C humid incubator supplemented with 5% CO₂.

Virus production, infection, and stable transfection

To generate a fusion protein of human ACE2 and red fluorescent protein (RFP), the hACE2 overexpressing lentivirus plasmid (pLV[Exp]-mCherry;T2A:Puromycin-EF1A>hACE2 [NM_021804.3], plasmid ID: VB200706-2658vya) and the control plasmid (pLV[Exp]-mCherry/Puromycin-EF1A>Stuffer300, plasmid ID: VB180713-1052gdp) with mCherry and puromycin dual reporter gene overexpression were purchased from VectorBuilder (Guangzhou 510663, PR China) and the package plasmids pLP1, pLP2, and pVSVG were from System Biosciences (Palo Alto, CA 94303, USA). For virus production, 4–5 × 10⁵ 293 T cells were seeded in a 6-well plate overnight to reach a density of 70–80% confluency at the time of transfection. The hACE2 overexpressing lentivirus plasmid or control plasmid were co-transfected with the three package plasmids into 293T cells using TransInTM EL Transfection Reagent (TransGen Biotech, Beijing 100192, PR China) according to the product manual of the supplier. Four to six hours after transfection, the cell culture medium was changed with 4 mL fresh DMEM and supplemented with 20% FBS and incubated for 48 h. The media were then collected and centrifuged at 1250 rpm for 5 min to collect the supernatant for harvesting the virus. The cancer cells MGC803 and Capan-2 were seeded at an appropriate density to attach overnight for virus infection. The media were then discarded and changed with a virus containing a supernatant with 6 μg/mL polybrene. Eight hours post-infection, the cell culture media were changed with a fresh medium supplemented with 10% FBS and incubated for 24 h. Puromycin (2 μg/mL) was then added to the cells for stably infected cell selection. The stably infected cells were further isolated using fluorescence-activated cell sorting with MoFlo (Beckman-Coulter, Brea, CA 92821-6232).

Co-culture of human cancer cells and HMVEC

HMVEC cells (2 × 10⁴) were seeded into a 96-well plate. After 12 h, 2 × 10⁴ MGC803 or Capan-2 cells, which had been stably transfected with lentiviral plasmid overexpressing ACE2-RFP fusion protein, were added into the wells. After 24 h, the co-cultured cells were observed by high content screening microscopy (ImageXpress Micro Confocal, Molecule Devices, USA) and images were taken every 15 min for the next 24 h.

Statistical analysis

Graphpad prism software version 8.0 (GraphPad Software, San Diego, CA, USA) was used for the statistical analyses. The two-sided Wilcoxon signed-rank test was used to compare ACE2 staining values between tumor tissues and normal tissues. Survival analysis was performed using the Kaplan–Meier methods and the log-rank test. A p < 0.05 was considered significant.

Results

ACE2 expression profiles in human tumors

Bioinformatics’ analyses have shown that ACE2 is aberrantly expressed in many types of tumors [3]. Our IHC analyses showed that ACE2 protein expression was significantly increased in colorectal adenocarcinoma, pancreatic adenocarcinoma, gastric adenocarcinoma, and papillary renal cell carcinoma cancer tissues compared with their corresponding normal tissues. It was significantly decreased in chromophobe
renal cell carcinoma, testicular germ cell tumors, and papillary thyroid carcinoma (Figures 1–2). Survival analyses showed that although gastric cancer and colorectal cancer patients had elevated ACE2 expression in their tumor tissues seemed to possess better overall survival, the difference was not statistically significant (Figure 3).

Figure 1. ACE2 protein expression in tumors and corresponding normal tissues. IHC staining of ACE2 was conducted in tumor tissues surrounding normal tissues including two tissue microarray sets of gastric cancer and colorectal cancer. ACE2, stained in brown, can be seen in the cytoplasm and cellular membrane.
ACE2 expression on tumor vasculature is limited to a portion of the tumor blood vessels

ACE2 expression in the endothelial cells of the tumor vasculature was observed in only 54% of the tumor blood vessels (Figure 4). Thus, ACE2 expression is negligible in some tumor vasculature, suggesting that this receptor is either replaceable or a surrogate ACE2 could be achieved by intercellular exchange of this protein.

ACE2 transfer from tumor cells into endothelial cells was not observed

To validate the existence of ACE2 intercellular transfer from tumor cells into endothelial cells, we co-cultured HMVEC cells with human gastric cancer cells MGC803 or pancreatic cancer cells Capan-2 for 24 h. The absence of ACE2 transfer from cancer cells into endothelial cells was confirmed (Videos 1–4). However, this in vitro experiment needs to be validated using a long-term culture or an in vivo experiment to exclude the possibility of ACE2 transferring from tumor cells into endothelial cells.

Discussion

Since December 2019, SARS-CoV-2 has spread worldwide. Evidence shows that SARS-CoV-2 uses ACE2 as its receptor [17, 18]. It seems that cancer patients have a higher risk of SARS-CoV-2 infection and poorer outcomes than...
Co-culturing MGC803 human gastric cancer cells with HMVEC cells. A time-lapse video monitoring the movement of the fusion protein ACE2-RFP (red) in cancer cells. Intercellular ACE2-RFP transfer from cancer cells into endothelial cells (green arrow) was not observed. https://vcm.edpsciences.org/10.1051/vcm/2021004#V1

Co-culturing MGC803 cells with HMVEC cells. Another time-lapse video with the same conditions as Video 1. Intercellular ACE2-RFP transfer from cancer cells into endothelial cells (green arrows) was not observed. https://vcm.edpsciences.org/10.1051/vcm/2021004#V2

Figure 4. ACE2 expression in the tumor vasculature. (A) Examples of ACE2 staining in the tumor vasculature. (B) For each cancer type, a total of 100 tumor microvessels were counted from 10 different tumor tissues, except for pancreatic adenocarcinoma, in which a total of 90 tumor microvessels were counted in 9 tumor tissues. Different cancer types had a varying percentage of ACE2 positive tumor microvessels, resulting in an average of only 54% tumor microvessels expressing ACE2.
COVID-19 patients without cancers [7, 19]. A recent study showed that 13 common cancers all had an increased risk of SARS-CoV-2 infection than patients without cancer, especially for those with blood cancer [20]. Moreover, newly diagnosed cancer patients are the most vulnerable among all cancer patients.

Consistent with the bioinformatics’ analysis that ACE2 mRNA was aberrantly expressed in many types of tumors [3], the elevated expression of ACE2 in the majority of tumor tissues found in our study might provide a clue to explaining this clinical phenomenon. Tumor cells over-expressing ACE2 have been proposed to provide the entrance for SARS-CoV-2 infection, and this entrance has been suspected to be shared between cancer cells and endothelial cells. However, when co-culturing HMVEC with human cancer cells overexpressing the ACE2-RFP fusion protein, we did not observe ACE2 transferring from tumor cells into endothelial cells.

The prognostic role of ACE2 in cancer patients without COVID-19 has been preliminarily evaluated. Elevated ACE2 expression in tumor tissues correlates with better patient prognosis in cancers of the liver [21], kidney [21], uterine endometrium [4], and the breast [5].

As to the mechanism underlying ACE2 aberrant expression, bioinformatics found neither mutations nor DNA copy variation was correlated with the overexpression of ACE2 [3]. In contrast, hypo DNA methylation of ACE2 has been found to be inversely correlated with ACE2 overexpression in cancer cells [3]. A reduced DNA methylation level is a possible reason for ACE2 overexpression in colon adenocarcinoma, rectal adenocarcinoma, pancreatic adenocarcinoma, rectum adenocarcinoma, and lung adenocarcinoma. While an increased DNA methylation level might be the cause of ACE2 being downregulated in testicular germ cell tumors.

Deteriorating factors of cancer patients with COVID-19 include being male, elderly, having more comorbidities, a history of smoking, cardiovascular disease, type 2 diabetes, obesity, asthma, radiotherapy, chemotherapy, and immunotherapy [19, 22, 23]. It is therefore believed that the impaired immune system in cancer patients might be a common reason for the increased risk of COVID-19 infection.

However, in the present study, we only applied short-term in vitro co-culture of the cells. Long-term cell culture using more types of endothelial cells as well as in vivo experiments are warranted to exclude the possibility of ACE2 transferring from tumor cells to endothelial cells.

Taken together, we found that ACE2 expression was upregulated in colorectal adenocarcinoma, pancreatic adenocarcinoma, gastric adenocarcinoma, and papillary renal cell carcinoma. While it was downregulated in chromophobe renal cell carcinoma, testicular germ cell tumors, and papillary thyroid carcinoma. Only half of the tumor vasculature expressed ACE2. Intercellular exchange of ACE2 from cancer cells into endothelial cells was not observed in our short-term cell co-culture.

Conflict of interest

The authors declare that they do not have any conflict of interest.

Acknowledgements. This work was partly supported by grants from the National Natural Science Foundation of China (No. 82073220,
No. 81872384, and No. 81672872 to C.Q., No. 81972785, No. 81773162, and No. 81572901 to B.H.), and a research program from Sun Yat-sen University (No. 84000-18843409 to C.Q.).

References